2025-09-15 - Analysis Report
Okay, here's an analysis of Hims & Hers Health Inc. (HIMS) based on the provided data.

**Hims & Hers Health Inc. (HIMS) Analysis**

**Company Overview:** Hims & Hers Health Inc. is a telehealth company offering personalized health and wellness solutions.

**1. Performance vs. S&P 500 (VOO)**

*   **HIMS Cumulative Return:** 212.78%
*   **VOO Cumulative Return:** 73.07%
*   **Absolute Divergence (Current):** 138.2
*   **Relative Divergence:** 60.6

**Analysis:** HIMS has significantly outperformed the S&P 500 (VOO) over the period. The relative divergence of 60.6 indicates that HIMS's performance is well above the historical average compared to the S&P 500.

**Alpha, Beta Analysis**

| Year       | CAGR      | MDD   | Alpha   | Beta   | Cap(B) |
| ---------- | --------- | ----- | ------- | ------ | ------ |
| 2019-2021  | -46.0%    | 51.0% | -84.0%  | -0.0   | 1.5    |
| 2020-2022  | -15.0%    | 72.1% | -17.0%  | -0.0   | 1.4    |
| 2021-2023  | -51.0%    | 72.1% | -69.0%  | -0.1   | 2.0    |
| 2022-2024  | 127.0%    | 78.4% | 101.0%  | -0.1   | 5.5    |
| 2023-2025  | 208.0%    | 80.7% | 151.0%  | -0.1   | 12.5   |

**Analysis:**

*   **CAGR (Compound Annual Growth Rate):**  CAGR is highly variable, with negative values for 2019-2023 and exceptionally high values for 2022-2025. This suggests significant volatility in HIMS's growth trajectory.
*   **MDD (Maximum Drawdown):**  MDD is consistently high across all periods, indicating substantial risk and potential for large losses.
*   **Alpha:** Alpha is mostly negative in earlier periods but turns strongly positive in later periods (2022-2025), indicating outperformance relative to the market during those times.
*   **Beta:** Beta is consistently negative and close to zero, suggesting very low correlation with the market. HIMS's price movements are largely independent of the broader market trends.
*   **Cap(B) (Market Capitalization):** Market cap has grown significantly from 2019-2021 to 2023-2025, indicating increasing investor confidence and company growth.

**2. Recent Price Action**

*   **Current Price:** 55.5
*   **Previous Close:** 51.76
*   **Change:** 7.23
*   **5-day Moving Average:** 50.494
*   **20-day Moving Average:** 46.125
*   **60-day Moving Average:** 50.246

**Analysis:**  The current price shows a substantial positive change from the previous close, indicating a strong upward move. The price is above all three moving averages (5, 20, and 60-day), suggesting bullish momentum. The large price change (7.23) suggests a possible breakout or significant event driving the stock higher.

**3. Market Risk Indicators and Expected Return**

*   **Market Risk Indicator (MRI):** 0.3233 (Low Risk)
*   **RSI:** 71.73 (Overbought)
*   **PPO:** 2.718
*   **Hybrid Signal:** cash_0%_Buy 90% of cash
*   **Recent (20-day) Relative Divergence Change:** +9.7 (Short-term increase)
*   **Expected Return:** -10.9% (Long-term, relative to S&P 500)

**Analysis:**

*   **MRI:** Indicates low market risk.
*   **RSI:** The RSI suggests that the stock is currently overbought, which could signal a potential pullback or consolidation in the near term.
*   **PPO:** Positive PPO values suggest that the short-term moving average is above the long-term moving average, confirming the bullish trend.
*   **Hybrid Signal:** The hybrid signal recommends using 90% of available cash to buy the stock, implying a strong buy recommendation.
*   **Relative Divergence Change:** The recent increase in relative divergence further supports the short-term upward trend.
*   **Expected Return:** While the current momentum is strong, the long-term expected return is negative compared to the S&P 500. This could suggest that the stock is currently overvalued, or that future growth is expected to be lower.
*   **Price Change Note:** The significant price change from the previous close reflects a notable event or strong buying pressure.

**4. Recent News & Significant Events**

*   **Hims & Hers Focus on Hormone Health:**  Positive, suggests expansion and growth potential.
*   **Stock Trades Up:**  Confirms positive momentum.
*   **Leads Growth Stocks:**  Highlights HIMS as a leader in its sector.
*   **Surges 64.1% in 6 Months:**  Indicates strong recent performance.
*   **Jumps on Testosterone Foray:**  Signals new product/service launches driving growth.

**Analysis:** Recent news is overwhelmingly positive, focusing on growth, new initiatives (hormone health, testosterone), and strong stock performance. These news items likely contribute to the recent price surge.

**4-2. Analyst Opinions**

*   **Consensus:** Hold (2.75)
*   **Target Price:**
    *   Average: 49.45
    *   High: 85.00
    *   Low: 28.00
*   **Recent Rating Changes:** No changes provided

**Analysis:** The analyst consensus is "Hold," which contrasts with the positive news and recent stock performance. The average target price (49.45) is below the current price (55.5), suggesting potential overvaluation. The wide range between the high and low target prices indicates uncertainty among analysts.

**5. Recent Earnings Analysis**

| 날짜       | EPS  | 매출       |
| ---------- | ---- | ---------- |
| 2025-08-04 | 0.19 | 0.54 B$    |
| 2025-05-05 | 0.22 | 0.59 B$    |
| 2024-11-04 | 0.35 | 0.40 B$    |
| 2024-08-05 | 0.06 | 0.32 B$    |
| 2025-08-04 | 0.06 | 0.32 B$    |

**Analysis:** Revenue and EPS show mixed results. From 2024-08-05 to 2025-05-05, both revenue and EPS increased. However, revenue declined from 0.59B$ in 2025-05-05 to 0.54B$ in 2025-08-04, and EPS declined as well.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
| ------------ | --------- | ------------- |
| 2025-06-30   | $0.54B   | 76.39%       |
| 2025-03-31   | $0.59B   | 73.50%       |
| 2024-12-31   | $0.48B   | 76.81%       |
| 2024-09-30   | $0.40B   | 79.16%       |
| 2024-06-30   | $0.32B   | 81.30%       |

**Capital and Profitability:**

| Quarter      | Equity    | ROE      |
| ------------ | --------- | -------- |
| 2025-06-30   | $0.56B   | 7.55%   |
| 2025-03-31   | $0.55B   | 9.01%   |
| 2024-12-31   | $0.48B   | 5.46%   |
| 2024-09-30   | $0.44B   | 17.18%  |
| 2024-06-30   | $0.36B   | 3.67%   |

**Analysis:**

*   **Revenue:** Revenue shows a generally increasing trend from mid-2024 to early 2025, but there's a slight decline in the most recent quarter (2025-06-30).
*   **Profit Margin:** Profit margins are consistently high (above 73%) but also show a slight decline in the most recent quarter.
*   **Equity:** Equity has steadily increased over the past year, indicating growth in the company's net assets.
*   **ROE (Return on Equity):** ROE is variable, with a high in Q3 2024 (17.18%) and fluctuating since then. The recent ROE is moderate.

**7. Overall Summary**

Hims & Hers Health Inc. (HIMS) is experiencing strong growth momentum, driven by positive news, new product launches, and a bullish market sentiment. Recent stock performance has been exceptional, significantly outperforming the S&P 500. However, several factors warrant caution:

*   **Overbought Condition:** The RSI indicates that the stock may be overbought, increasing the risk of a pullback.
*   **Analyst Consensus:** Analysts have a "Hold" rating and an average target price below the current price, suggesting potential overvaluation.
*   **Long-Term Expected Return:** The negative long-term expected return compared to the S&P 500 raises concerns about future growth prospects or current valuation.
*   **Variable Financial Metrics:** While revenue and equity have generally increased, there are recent signs of slowing growth and declining profit margins and ROE.

**Conclusion:**

HIMS is a growth stock with significant potential, but investors should be aware of the risks associated with its current valuation and the potential for a correction. A cautious approach may be warranted, considering the overbought condition and analyst sentiment.  Further monitoring of financial performance and news events is crucial.
